Autifony Therapeutics hosts symposium ‘Schizophrenia: a treatable brain disorder’ at British Association for Psychopharmacology
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and serious disorders of the nervous system, today hosted a satellite symposium at the British Association for Psychopharmacology 40th Anniversary Summer Meeting to raise the profile of its pioneering new schizophrenia programme, now in preclinical development.
